RNAi-mediated knockdown of target genes: a promising strategy for pancreatic cancer research

Chang, Hong

doi:10.1038/sj.cgt.7701063

Cited by 28 publications

(17 citation statements)

References 83 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…5,7,35,40,53 Several genetic and epigenetic changes may be involved in the pancreatic carcinogenesis, including activation of oncogenes, inactivation of tumor suppressor genes, and deregulation of signal transduction pathways. Recent advances in the understanding of developmental signaling pathways in pancreatic cancer have led to new insights into the mechanisms of pancreatic carcinogenesis.…”

Section: Discussionmentioning

confidence: 99%

PDX-1 Acts as a Potential Molecular Target for Treatment of Human Pancreatic Cancer

Liu¹,

Ballian²,

Belaguli³

et al. 2008

Pancreas

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

PDX-1 Acts as a Potential Molecular Target for Treatment of Human Pancreatic Cancer

Liu¹,

Ballian²,

Belaguli³

et al. 2008

Pancreas

View full text Add to dashboard Cite

show abstract

“…Since RNAi is specific and efficiently silences the target mRNAs, resulting in a global knockdown of oncogenic proteins, it may be possible to treat any stage of cancer. Recent studies explored a number of cancer-causing genes [23], and several have been identified as potential targets for siRNA-based therapy [24], [25]. Thus, RNAi has affected cancer therapy by downregulating tumorigenic genes, resulting in pro-apoptotic and anti-metastatic effects, while having negligible effects on healthy tissues.…”

Section: Sirna-based Gene Silencing and Its Role In Cancer Therapymentioning

confidence: 99%

Nanoparticles for siRNA-Based Gene Silencing in Tumor Therapy

Babu

Muralidharan

Amreddy

et al. 2016

IEEE Trans.on Nanobioscience

View full text Add to dashboard Cite

Gene silencing through RNA interference (RNAi) has emerged as a potential strategy in manipulating cancer causing genes by complementary base-pairing mechanism. Small interfering RNA (siRNA) is an important RNAi tool that has found significant application in cancer therapy. However due to lack of stability, poor cellular uptake and high probability of loss-of-function due to degradation, siRNA therapeutic strategies seek safe and efficient delivery vehicles for in vivo applications. The current review discusses various nanoparticle systems currently used for siRNA delivery for cancer therapy, with emphasis on liposome based gene delivery systems. The discussion also includes various methods availed to improve nanoparticle based-siRNA delivery with target specificity and superior efficiency. Further this review describes challenges and perspectives on the development of safe and efficient nanoparticle based-siRNA-delivery systems for cancer therapy.

show abstract

“…Pancreatic cancer is one of the most common cancer type with a very poor prognosis, partially due to its very low accessibility to resection and resistance to chemoradiotherapy [37]. An miRNA based treatment of pancreatic cancer thereafter appears to be an important alternative towards cancer therapy as miRNAs can be directed against pancreatic cancer through various pathways, including the inhibition of overexpressed oncogenes, suppressor of tumor growth and enhancement of apoptosis.…”

Section: Involvement Of Mirna In Human Cancermentioning

confidence: 99%

Development of the human cancer microRNA network

Bandyopadhyay

Mitra

Maulik

et al. 2010

Silence

210

157

View full text Add to dashboard Cite

BackgroundMicroRNAs are a class of small noncoding RNAs that are abnormally expressed in different cancer cells. Molecular signature of miRNAs in different malignancies suggests that these are not only actively involved in the pathogenesis of human cancer but also have a significant role in patients survival. The differential expression patterns of specific miRNAs in a specific cancer tissue type have been reported in hundreds of research articles. However limited attempt has been made to collate this multitude of information and obtain a global perspective of miRNA dysregulation in multiple cancer types.ResultsIn this article a cancer-miRNA network is developed by mining the literature of experimentally verified cancer-miRNA relationships. This network throws up several new and interesting biological insights which were not evident in individual experiments, but become evident when studied in the global perspective. From the network a number of cancer-miRNA modules have been identified based on a computational approach to mine associations between cancer types and miRNAs. The modules that are generated based on these association are found to have a number of common predicted target onco/tumor suppressor genes. This suggests a combinatorial effect of the module associated miRNAs on target gene regulation in selective cancer tissues or cell lines. Moreover, neighboring miRNAs (group of miRNAs that are located within 50 kb of genomic location) of these modules show similar dysregulation patterns suggesting common regulatory pathway. Besides this, neighboring miRNAs may also show a similar dysregulation patterns (differentially coexpressed) in the cancer tissues. In this study, we found that in 67% of the cancer types have at least two neighboring miRNAs showing downregulation which is statistically significant (P < 10-7, Randomization test). A similar result is obtained for the neighboring miRNAs showing upregulation in specific cancer type. These results elucidate the fact that the neighboring miRNAs might be differentially coexpressed in cancer tissues as that of the normal tissue types. Additionally, cancer-miRNA network efficiently detect hub miRNAs dysregulated in many cancer types and identify cancer specific miRNAs. Depending on the expression patterns, it is possible to identify those hubs that have strong oncogenic or tumor suppressor characteristics.ConclusionsLimited work has been done towards revealing the fact that a number of miRNAs can control commonly altered regulatory pathways. However, this becomes immediately evident by accompanying the analysis of cancer-miRNA relationships in the proposed network model. These raise many unaddressed issues in miRNA research that have never been reported previously. These observations are expected to have an intense implication in cancer and may be useful for further research.

show abstract

RNAi-mediated knockdown of target genes: a promising strategy for pancreatic cancer research

Cited by 28 publications

References 83 publications

PDX-1 Acts as a Potential Molecular Target for Treatment of Human Pancreatic Cancer

PDX-1 Acts as a Potential Molecular Target for Treatment of Human Pancreatic Cancer

Nanoparticles for siRNA-Based Gene Silencing in Tumor Therapy

Development of the human cancer microRNA network

Contact Info

Product

Resources

About